Tessellate BIO
Redefining Synthetic Lethality beyond HRD
Redefining Synthetic Lethality beyond HRD
Tessellate BIO is a biotechnology startup that is redefining Synthetic Lethality through the discovery and development of novel precision oncology medicines. Founded in 2020 and headquartered in The Netherlands, the company aims to revolutionize cancer treatment with the mission of turning cancer patients into cancer survivors.
With a focus on developing drugs that target unexplored or difficult to drug pathways beyond HRD, Tessellate BIO operates as a private preclinical stage biotechnology company. The company's research labs are located at the Stevenage Bioscience Catalyst, UK, highlighting its commitment to cutting-edge innovation in the field.
The startup recently secured a significant milestone with an €8.00M Seed Round investment on 17 October 2023. This investment came from top-tier life science investors BioGeneration Ventures (BGV) and Forbion, further solidifying the company's standing in the biotechnology industry.
Overall, Tessellate BIO's dedication to pushing the boundaries of cancer treatment and its strategic partnerships with renowned investors position it as a promising player in the biotechnology landscape, with potential for significant impact in the field of precision oncology.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | €8.00M | 2 |
|
17 Oct 2023 |
No recent news or press coverage available for Tessellate BIO.
We care about your data, and we'd love to use cookies make your experience better.
